Pilot Study of Minocycline in Huntington's Disease
A Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's Disease
Sponsor: FDA Office of Orphan Products Development
Listed as NCT00277355, this PHASE2/PHASE3 trial focuses on Huntington Disease and remains completed. Sponsored by FDA Office of Orphan Products Development, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- FDA Office of Orphan Products Development
- Merit Cudkowicz
For direct contact, visit the study record on ClinicalTrials.gov .